Last reviewed · How we verify
Ixabepilone + Capecitabine
Ixabepilone stabilizes microtubules to prevent cell division, while capecitabine is a prodrug that converts to fluorouracil to inhibit DNA synthesis, together providing synergistic cytotoxic activity against cancer cells.
Ixabepilone stabilizes microtubules to prevent cell division, while capecitabine is a prodrug that converts to fluorouracil to inhibit DNA synthesis, together providing synergistic cytotoxic activity against cancer cells. Used for Metastatic or locally advanced breast cancer, HER2-negative breast cancer.
At a glance
| Generic name | Ixabepilone + Capecitabine |
|---|---|
| Also known as | BMS-247550, IXEMPRA, Epothilone, IXEMPRA® |
| Sponsor | R-Pharm |
| Drug class | Microtubule stabilizer + Antimetabolite |
| Target | β-tubulin (ixabepilone); Thymidylate synthase (capecitabine/5-FU) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ixabepilone is a microtubule-stabilizing agent (taxane analog) that binds to β-tubulin and prevents microtubule depolymerization, disrupting mitotic spindle formation and inducing apoptosis. Capecitabine is a fluoropyrimidine carbamate that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. The combination exploits complementary mechanisms of action for enhanced antitumor efficacy.
Approved indications
- Metastatic or locally advanced breast cancer
- HER2-negative breast cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Fatigue
- Nausea
- Diarrhea
- Hand-foot skin reaction
- Myalgia/arthralgia
Key clinical trials
- Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer (PHASE1, PHASE2)
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (PHASE3)
- The BEACON Study (Breast Cancer Outcomes With NKTR-102) (PHASE3)
- Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer (PHASE3)
- Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer (PHASE3)
- Breast Cancer Treatment Based on Organ-like Culture
- A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer (PHASE2)
- Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ixabepilone + Capecitabine CI brief — competitive landscape report
- Ixabepilone + Capecitabine updates RSS · CI watch RSS
- R-Pharm portfolio CI